Skip to main content
. 2022 Aug 19;23(16):9345. doi: 10.3390/ijms23169345

Figure 5.

Figure 5

The combination of sorafenib and doxorubicin caused inhibition of cell cycle progression, resulting in G2/M arrest in D17 cells. Cell cycle distribution of D17 OSA cells treated with either (A) DMSO (control), (B) sorafenib 5 µM, (C) doxorubicin 100 nM, or (D) both sorafenib 5 µM plus doxorubicin 100 nM for 24 h. Representative flow histograms demonstrate changes in the cell cycle progression on canine OSA D17 cell line. The combination of sorafenib and doxorubicin resulted in a cell arrest at the G2/M phase. Representative cell cycle distribution graphs show G2/M cell arrest in (E) D17, (F) Abrams and human OSA, and (G) SAOS2 cell lines. ***: p < 0.001 for G2/M arrest compared to the combined treatment (5 µM sorafenib and 100 nM doxorubicin) as determined by one-way ANOVA with Dunnett’s multiple comparison test.